Cancer drug discovery faces the FACT

Sci Transl Med. 2011 Aug 10;3(95):95ps34. doi: 10.1126/scitranslmed.3002822.

Abstract

In this issue of Science Translational Medicine, Gasparian et al. use a clever cell-based screen to identify a family of DNA-binding small molecules-curaxins-that inhibit tumor cell growth and division. The curaxins' mechanism of action pinpoints a new chromatin-remodeling factor as a therapeutic target for cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • DNA-Binding Proteins / metabolism*
  • High Mobility Group Proteins / metabolism*
  • Humans
  • NF-kappa B / antagonists & inhibitors*
  • Transcriptional Elongation Factors / metabolism*
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Antineoplastic Agents
  • DNA-Binding Proteins
  • High Mobility Group Proteins
  • NF-kappa B
  • SSRP1 protein, human
  • Transcriptional Elongation Factors
  • Tumor Suppressor Protein p53